Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medivolve Inc MEDVF

Medivolve, Inc. is a Canada-based healthcare technology company. The Company has two business units: Medivolve Pharmacy Division (MPD) and Collection Sites Diagnostics (CSD). MPD provides retail pharmacy and mail-order pharmacy services related to COVID-19, antibiotics, dermatology, family medicine, immunology, neurology, pain management, pediatrics, preventive medicine, and psychiatry to patients in Southern California. CSD’s software platform, Electronic Health Records app (EHR), is focused on supporting clinical staff, is a series of assets and functionalities that enhance the customer experience and provide an end-to-end lab solution. The Company, through its subsidiaries, Medivolve Pharmacy Inc., and Kedy Ying Jao D.O., a medical corporation, operate a distributed network of two retail patient-care locations in California, United States. The Company has served hundreds of thousands of patients across the United States and facilitated more than 1,533,000 clinical tests.


OTCPK:MEDVF - Post by User

Post by Sarb99on Jun 17, 2020 5:34pm
160 Views
Post# 31162242

PCL Application submitted to FDA and Health Canada

PCL Application submitted to FDA and Health Canada
  1. PCL application submitted to both USA FDA and Health Canada and decision can come any day.
  2. Sunnybrook making good progress
  3. Sinai (Lunenfeld-Tanenbaum Research Institute (LTRI) doing good work
  4. Once PCL testing get approval, they already have some orders and for starting 500,000 tests sold for $25 each is not bad revenue. Once FDA or health Canada reviewer as you question and you get back to them with answers, then I should not take much longer to get approval. I be happy with 4-5 million tests a moth does not care if they can or can not ramp up more than that.
  5. Yes, buying Glenco Medical seems little too expensive but if Glen Copeland can bring in 15-20 sports teams into contracts then I can probably forgive them.
  6. As per Amino Therapeutics, I think they probably not ready yet for any update. I think he did say other partners can come next time.
  7. I see my investment should be worthwhile once they get approval and start selling those tests. Plus, we also have some good progress at Sunnybrook and Sinai. Then let’s see what Amino Therapeutics brings to the table, they have some good people working and also can get help from the parent company https://www.xenomics.com/

<< Previous
Bullboard Posts
Next >>